Functional analysis and molecular modeling show a preserved wild-type activity of p53C238Y

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1467-1473

  Ferrone, Marco ^a   Perrone, Federica ^b   Tamborini, Elena ^b   Paneni, Maria Silvia ^a   Fermeglia, Maurizio ^a   Suardi, Simona ^b   Pastore, Elisa ^b   Delia, Domenico ^b   Pierotti, Marco A ^b   Pricl, Sabrina ^a   Pilotti, Silvana ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; SERINE;

ADULT; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CASE REPORT; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC CONSERVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MAMMAL CELL; MISSENSE MUTATION; MOLECULAR GENETICS; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NERVE SHEATH TUMOR; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; SOUTHERN BLOTTING; WILD TYPE;

ADULT; BLOTTING, SOUTHERN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE AMPLIFICATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; NERVE SHEATH NEOPLASMS; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746079646     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0012     Document Type: Article

References (33)

1. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-908.
2. Freedman DA, Levine AJ. Nuclear export is required for degradation of enclogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998;18:7288-93.
3. Cordon-Cardo C, Latres E, Drobnjak N, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
4. Pilotti S, Della Torre G, Lavarino C, et al. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol 1997;181:14-24.
5. Momand J, Jung D, Wilcynski S, Nilan J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
6. Birindelli S, Perrone F, Oggionni M, et al . Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 2001;81:833-44.
7. INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 2003;9:4132-8.
8. Butò S, Pierotti MA, Tamborini E, et al. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection. Diagn Mol Pathol 1999;8:125-30.
9. Case DA, Pearlman DA, Caldwell JW, et al. AMBER 7. San Francisco (CA): University of California; 2000.
10. Cornell WD, Cieplak P, Bayly CI, et al. A second generation force field for the simulation of proteins and nucleic acids. J Am Chem Soc 1995; 117:5179-97.
11. Sanner MF, Olson AJ, Spehner JC. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 1996;38:305-20.
12. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-65
13. Reyes CM, Kollman PA. Investigating the binding specificity of U 1A-RNA by computational mutagenesis. J Mol Biol 2000;295:1-6.
14. Pricl S, Fermeglia M, Ferrone M, Tamborini E. T3151-mutated Bcr-Abl in chronic myeloid leucemia and imatinib; insights from a computational study. Mol Cancer Ther 2005;4:1167-74.
15. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926-35.
16. Darden T, York D, Pedersen L. Particle mesh Ewald-an Nlog(N) method for Ewald sums in large systems. J Chem Phys 1993;98:1089-92.
17. Srinivasan J, Cheathem TE III, Cieplak P, Kollman PA, Case DA. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J Am Chem Soc 1993;120:9401-9.
18. Gilson MK, Sharp KA, Honig B. Calculating the electrostatic potential of molecules in solution: method and error assessment. J Comput Chem 1987;9:327-35.
19. Honig B, Nicholls A. Classical electrostatics in biology and chemistry. Science 1995;268:1144-9.
20. Sitkoff D, Sharp KA, Honig B. Accurate calculation of hydration free energies using macroscopic solvent models. J Phys Chem 1994;98:1978-88.
21. Brooks BR, Janežič D, Karplus M. Harmonic analysis of large systems. 1. Methodology. J Comput Chem 1995;16:1522-42.
22. Marti-Renom MA, Stuart A, Fiser A, Sánchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000;29:291-325.
23. Laskowski RA, MacArthur MW, Moss DS, Thornton JIM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993;26:283-91.
24. Rhodriguez R, Chinea G, Lopez N, Pons T, Vriend G. Homology modeling, model and software evaluation: three related sources. CABIOS 1998;14:523-8.
25. Bell S, Klein C, Willer L, Hansen S, Buchner J. p53 contains large unstructured regions in its native state. J Mol Biol 2002;322:917-27.
26. Delphin C, Cahen P, Lawrence JJ, Baudier J. Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. Eur J Biochem 1994;223:683-92.
27. Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol 1995;15:3892-903.
28. Buzek J, Latonen L, Kurki S, Peltonen K, Laiho M. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res 2002;30:2340-8.
29. Sun XZ, Vinci C, Makmura L, et al. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid Redox Signal 2003;5:655-65.
30. Pivonkova H, Brazdova M, Kasparkova J, Brabec V, Fojta M. Recognition of cisplatin-damaged DNA by p53 protein: critical role of the p53 C-terminal domain. Biochem Biophys Res Commun 2006;339:477-84.
31. Bullock AN, Henckel J, DeDecker BS, et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A 1997;94:14338-42.
32. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000;19:1245-56.
33. Pace CN, Horn G, Herbert EJ, et al. Tyrosine hydrogen bends make a large contribution to protein stability. J Mol Biol 2001;321:393-404.